Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	6.92	8.19	6.71	23.54	4.43
Revenue Growth (YoY)	-27.17%	21.95%	-71.49%	431.67%	-
Cost of Revenue	0.71	2.3	3.35	10.98	1.89
Gross Profit	6.21	5.89	3.36	12.56	2.54
Selling, General & Admin	3.99	3.44	1.27	2.17	0.09
Research & Development	0.46	0.45	0.13	0.2	-
Total Operating Expenses	4.44	3.89	1.4	2.37	0.09
Operating Income	1.76	2	1.96	10.2	2.46
Interest Income	0.34	0.34	0.17	0.04	-
Interest Expense	-	-	-	-0.01	-
Other Non-Operating Income (Expense)	0.47	0.04	0.13	-0.22	0.08
Total Non-Operating Income (Expense)	0.81	0.38	0.29	-0.18	0.08
Pretax Income	2.57	2.37	2.25	10.01	2.54
Net Income	2.57	2.37	2.25	10.01	2.54
Net Income to Common	2.57	2.37	2.25	10.01	2.54
Net Income Growth	-40.55%	5.29%	-77.49%	294.79%	-
Shares Outstanding (Basic)	43	42	21	0	0
Shares Outstanding (Diluted)	43	42	21	0	0
Shares Change (YoY)	0.96%	97.30%	21435216.00%	-	-
EPS (Basic)	0.05	0.06	0.10	100112.00	25358.00
EPS (Diluted)	0.05	0.06	0.10	100112.00	25358.00
EPS Growth	-	-46.67%	-100.00%	294.80%	-
Shares Outstanding	143.89	42.29	42.29	0	0
Free Cash Flow	-	2.08	0.9	4.45	4.18
Free Cash Flow Growth	-	131.57%	-79.81%	6.40%	-
Free Cash Flow Per Share	-	0.05	0.04	44488.46	41813.25
Gross Margin	89.70%	71.90%	50.07%	53.36%	57.40%
Operating Margin	25.49%	24.38%	29.22%	43.30%	55.46%
Profit Margin	37.20%	28.99%	33.58%	42.52%	57.26%
FCF Margin	-	25.42%	13.38%	18.90%	94.42%
EBITDA	1.76	2	1.97	10.2	2.46
EBITDA Margin	25.49%	24.38%	29.39%	43.33%	55.46%
EBIT	1.76	2	1.96	10.2	2.46
EBIT Margin	25.49%	24.38%	29.22%	43.30%	55.46%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q